• ATRIVA Therapeutics

    First-in-class inhibitors against respiratory viral infections

    Read More

  • Invest in research to maximize profits!

    Projected retail peak sales of Atriva’s MEK inhibitor ATR-002 in the indication “Influenza in high-risk patients”, as per-oral treatment regime over 5 days could be in excess of € 600 Mio without considering pandemic events or additional indications.

    Read More

  • 1
  • 2

The ATRIVA Approach

Already in 2001 our scientists published a new antiviral mode of action.


Read more


ATRIVA aims to develop new antiviral therapies against different respiratory viral infections.


Read more


The target indication for our lead compound ATR-002, is represented by “Influenza in high-risk patients”.


Read more

About Us

Learn more about the people from Atriva Therapeutics GmbH.

Read more

Atriva About us

First-in-class inhibitors against
respiratory viral infections

ATRIVA aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVA attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections.
ATRIVA closed a seed financing of € 3 Mn in late 2016. The proceeds of this allows the company to reach clinical development with its lead project ATR-002 for influenza in high-risk patients. We invite you to explore our approach and pipeline presented on this website and encourage you to contact us directly.
Demo Image

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium.

Contact Form

Please, enter your name
Please, enter your phone number
Please, enter your e-mail address Mail address is not not valid
Please, enter your message


Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.